CSIMarket



Ocugen Inc.  (OCGN)
Other Ticker:  
 
 

OCGN's Capital Expenditures Growth by Quarter and Year

Ocugen's Capital Expenditures results by quarter and year




OCGN Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 0.07 0.25 0.03
III Quarter September - 0.35 0.02 -
II Quarter June 1.37 0.26 -0.02 -0.79
I Quarter March 0.22 0.26 0.05 1.48
FY   1.59 0.94 0.30 0.72



OCGN Capital Expenditures second quarter 2022 Y/Y Growth Comment
Ocugen Inc. achieved in the second quarter 2022, above Company average Capital Expenditures surge of 425.38% year on year, to $ 1.37 millions.

Looking into second quarter 2022 results within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Capital Expenditures growth. While Ocugen Inc.' s Capital Expenditures doubling of 425.38% ranks overall at the positon no. 64 in the second quarter 2022.




OCGN Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -72 % 733.33 % -97.62 %
III Quarter September - 1650 % - -
II Quarter June 425.38 % - - -
I Quarter March -15.38 % 420 % -96.62 % 3600 %
FY   - 213.33 % -58.33 % -52 %

Financial Statements
Ocugen's second quarter 2022 Capital Expenditures $ 1.37 millions OCGN's Income Statement
Ocugen's second quarter 2021 Capital Expenditures $ 0.26 millions Quarterly OCGN's Income Statement
New: More OCGN's historic Capital Expenditures Growth >>


OCGN Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -80 % 1150 % -
III Quarter September - 34.62 % - -
II Quarter June 520.91 % 0 % - -
I Quarter March 214.29 % 4 % 66.67 % 17.46 %
FY (Year on Year)   - 213.33 % -58.33 % -52 %




Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #18
Overall #64

Capital Expenditures Y/Y Growth Statistics
High Average Low
270.26 % 76.55 % -16.56 %
(Dec 31 2020)   (Dec 31 2021)
Capital Expenditures second quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #18
Overall #64
Capital Expenditures Y/Y Growth Statistics
High Average Low
270.26 % 76.55 % -16.56 %
(Dec 31 2020)   (Dec 31 2021)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Ocugen's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1224.58 % 270.82 % -81.43 %
(Dec 31 2019)  


OCGN's II. Quarter Q/Q Capital Expenditures Comment
Ocugen Inc. achieved in the II. Quarter 2022 above company average sequential Capital Expenditures doubling of 520.91%, to $ 1.37 millions, from $0.22 millions in the first quarter.
OCGN is undergoing a remarkable growth, with recording above normal growth, and additionally accelerating pace, Cameron  Johnson, market insider situated in Chicago mentioned.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Ocugen's Capital Expenditures growth quarter on quarter, overall rank is 62.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #17
Overall #62
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #17
Overall #62
Capital Expenditures Q/Q Growth Statistics
High Average Low
1224.58 % 270.82 % -81.43 %
(Dec 31 2019)  


OCGN's II. Quarter Q/Q Capital Expenditures Comment
Ocugen Inc. achieved in the II. Quarter 2022 above company average sequential Capital Expenditures doubling of 520.91%, to $ 1.37 millions, from $0.22 millions in the first quarter.
Biotechnology & Pharmaceuticals company is undergoing a remarkable growth, not only recording better then normal growth, but also increasing speed.

Within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Ocugen's Capital Expenditures growth quarter on quarter, overall rank is 62.


Ocugen's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 2.00 $ 0.90 $ 0.94 $ 1.13 $ 0.80
Y / Y Capital Expenditures Growth (TTM) 151.64 % 74.89 % 206.04 % 1258 % -
Year on Year Capital Expenditures Growth Overall Ranking # 223 # 410 # 326 # 37 # 419
Seqeuential Capital Expenditures Change (TTM) 122.42 % -4.05 % -16.56 % 41.31 % 54.58 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 64 # 2361 # 2659 # 388 # 209




Cumulative Capital Expenditures growth Comment
Although Ocugen's Annual Capital Expenditures growth year on year were below company's average 1119.92% , Capital Expenditures announced in the Jun 30 2022 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 151.64% year on year, from 74.89% in Mar 31 2022.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 223, from total ranking in previous quarter at 410.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
270.26 %
76.55 %
-16.56 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 45
Overall # 223

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3909.05 %
1119.92 %
74.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 18
S&P 500 # 64
Cumulative Capital Expenditures growth Comment
Although Ocugen's Annual Capital Expenditures growth year on year were below company's average 1119.92% , Capital Expenditures announced in the Jun 30 2022 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 151.64% year on year, from 74.89% in Mar 31 2022.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 223, from total ranking in previous quarter at 410.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
270.26 %
76.55 %
-16.56 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 45
Overall # 223

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3909.05 %
1119.92 %
74.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 18
S&P 500 # 64




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
OCGN's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for OCGN's Competitors
Capital Expenditures Growth for Ocugen's Suppliers
Capital Expenditures Growth for OCGN's Customers

You may also want to know
OCGN's Annual Growth Rates OCGN's Profitability Ratios OCGN's Asset Turnover Ratio OCGN's Dividend Growth
OCGN's Roe OCGN's Valuation Ratios OCGN's Financial Strength Ratios OCGN's Dividend Payout Ratio
OCGN's Roa OCGN's Inventory Turnover Ratio OCGN's Growth Rates OCGN's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Jun 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Jun 30 2022
Agenus Inc712.86%$ 712.863 millions
Glycomimetics Inc.707.25%$ 707.252 millions
Intra cellular Therapies Inc.706.87%$ 706.875 millions
Tela Bio Inc.700.00%$ 700.000 millions
Forma Therapeutics Holdings Inc.700.00%$ 700.000 millions
Hydrofarm Holdings Group Inc.680.23%$ 680.228 millions
Agios Pharmaceuticals Inc.673.49%$ 673.494 millions
Tarsus Pharmaceuticals Inc.662.50%$ 662.500 millions
Kezar Life Sciences Inc.658.33%$ 658.333 millions
Tcr2 Therapeutics Inc.656.52%$ 656.516 millions
Pmv Pharmaceuticals Inc.637.12%$ 637.124 millions
Alpine Immune Sciences Inc.616.67%$ 616.667 millions
Sonida Senior Living Inc.614.90%$ 614.896 millions
Surgepays Inc.591.75%$ 591.754 millions
Sensus Healthcare Inc.542.86%$ 542.857 millions
Vor Biopharma Inc.534.60%$ 534.603 millions
Biolargo Inc.527.27%$ 527.273 millions
Icosavax Inc.513.73%$ 513.732 millions
Acumen Pharmaceuticals Inc.500.00%$ 500.000 millions
Nanostring Technologies Inc.492.09%$ 492.086 millions
Twist Bioscience Corporation485.45%$ 485.451 millions
Armata Pharmaceuticals Inc.479.59%$ 479.592 millions
Applied Molecular Transport Inc.453.10%$ 453.103 millions
Dariohealth Corp.448.28%$ 448.276 millions
Voyager Therapeutics Inc.447.14%$ 447.137 millions
Viridian Therapeutics Inc.440.74%$ 440.741 millions
Maxcyte inc.435.39%$ 435.387 millions
Ocugen Inc.419.39%$ 419.392 millions
Caribou Biosciences Inc.417.79%$ 417.787 millions
Lifestance Health Group Inc.405.18%$ 405.176 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CONN's Profile

Stock Price

CONN's Financials

Business Description

Fundamentals

Charts & Quotes

CONN's News

Suppliers

CONN's Competitors

Customers & Markets

Economic Indicators

CONN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071